Table 4 (A) OS (P=0.1; log-rank statistics) and (B) DFS (P=0.04; log-rank statistics) for patient subgroups, by integrated pathological and clinical tumour response
From: Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome
| Â | Integrated clinical and pathological response | N | No. of patients a | 5-years OS (%) | Median OS in years (95% CI) |
|---|---|---|---|---|---|
A, OS | Â | Â | Â | Â | Â |
I. | pCR | 3 | 2 | 33 | 1.5 (0.9–2.1) |
II. | pMRD and cCR | 4 | 3 | 25 | 3.4 (0.6–6.2) |
III. | pMRD and cPR/cSD | 7 | 1 | 100 | 7.3 (7.1–7.6) |
IV. | pHRTM and cCR/cPR | 39 | 20 | 61 | 6.5 (4.7–8.2) |
V. | pNR and cCR/cPR | 19 | 10 | 58 | 5.6 (ND) |
VI. | pHRTM and cSD | 7 | 5 | 43 | 3.1 (0–6.6) |
VII. | pNR and cSD | 10 | 5 | 47 | 4.3 (ND) |
| Â | Integrated clinical and pathological response | N | No. of patients b | 5-years OS (%) | Median OS in years (95% CI) |
B, DFS | Â | Â | Â | Â | Â |
I. | pCR | 3 | 3 | 33 | 1.3 (0.7–2.0) |
II. | pMRD and cCR | 4 | 3 | 25 | 1.7 (0.3–3.1) |
III. | pMRD and cPR/cSD | 7 | 1 | 86 | ND (ND) |
IV. | pHRTM and cCR/cPR | 39 | 25 | 44 | 4.3 (3.3–5.3) |
V. | pNR and cCR/cPR | 19 | 11 | 47 | 3.7 (0–7.6) |
VI. | pHRTM and cSD | 7 | 6 | 14 | 3.0 (0–9.0) |
VII. | pNR and cSD | 10 | 5 | 50 | 3.9 (ND) |
